In:
Diabetic Medicine, Wiley, Vol. 32, No. 12 ( 2015-12), p. 1555-1567
Abstract:
The data in this study show that the improvements in glycaemic control, weight and systolic blood pressure achieved with empagliflozin as add‐on to metformin after 24 weeks' treatment were sustained at week 76 and that empagliflozin was well tolerated over 76 weeks of treatment. Empagliflozin plus metformin may provide an attractive treatment option for people with Type 2 diabetes unable to achieve glycaemic control with metformin alone.
Type of Medium:
Online Resource
ISSN:
0742-3071
,
1464-5491
DOI:
10.1111/dme.2015.32.issue-12
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
2019647-7